When diagnosed with a disease, it’s often overwhelming to sort through mountains of medical data to figure out what therapies are available, pinpoint where they’re offered and identify the best experts to help. Complexity specialist Gunjan Bhardwaj recognizes that mining this information may best be done using a system of artificial intelligence and blockchain to help people, within and outside the medical field, navigate and comprehend such “deep, dense and diverse” data — entering a new era where all research is searchable and shareable.
Gunjan Bhardwaj studied at IIT Bombay, FH Pforzheim, MIT Sloan and EBS Oestrich-Winkel. He founded Innoplexus in 2011, a technology and product development company focused on solving challenges in life sciences and pharmaceuticals using artificial intelligence. Previously, he worked for BCG and EY. He has authored numerous articles for the Harvard Business Review, the MIT Sloan Review and other journals, and has advised businesses and nonprofit organizations. He lectures at the Frankfurt School of Finance and other schools.
Innoplexus, a leading AI and Life Sciences company, raises double-digit million dollar series C round from FinLab EOS VC and others
Frankfurt, Germany – Innoplexus AG, a leading global artificial intelligence (AI) company with over 80 patent applications in AI, machine learning and blockchain technologies, has received series C funding in the sum of double-digit millions. The round was co-led by FinLab EOS VC Fund, a venture capital fund backed by both Block.one, the publisher of the blockchain protocol EOSIO, and FinLab AG, one of Europe’s largest company builders and investors focused on financial services technologies. The FinLab EOS VC Fund invests across sectors and focuses on projects delivering value through the application of the EOSIO blockchain technology. Innoplexus AG represents FinLab EOS VC Fund’s largest investment to date.
Co-lead investor was existing shareholder ATAI Life Sciences, a global biotech company builder focused on developing breakthrough innovations in mental health. Innoplexus and ATAI closely cooperate to make the drug development process in mental health more effective and efficient by utilizing Innoplexus’ technology.
Innoplexus will use the funding to continue developing its AI and blockchain solutions and for international commercial expansion. “We are pleased to have gained yet another strong investor with the FinLab EOS VC Fund, who will support us to scale even further with their know-how and network,” says Dr. Gunjan Bhardwaj, Founder and CEO of Innoplexus.
Innoplexus’ products & solutions are used by global pharmaceutical and biotechnology companies as well as Clinical Research Organizations generating actionable insights across the drug development life cycle. The company is ushering in a new paradigm in drug discovery and development with its domain specific AI. Innoplexus is working with cutting edge technologies related to information retrieval, network analysis, computer vision, entity normalization and ontologies and has a strong focus on creating proprietary intellectual property.
“We fully believe in the mission of Innoplexus and will support them in transforming drug discovery and development into the areas of AI and blockchain. By integrating the EOSIO protocol, meaningful unpublished data could also be used for research. Innoplexus is leveraging the EOSIO blockchain to integrate unpublished data, as well as information that is trapped in silos, to aggregate growing data oceans and to accelerate drug discovery and development,’’ shares Juan Rodriguez, Managing Director of FinLab EOS VC Fund.
Image Credit: Innoplexus
News This Week
Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble [...]
A technology developed at Vanderbilt University Medical Center has led to the discovery of an "ultra-potent" monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. The antibody [...]
Research has found a significant fall in levels of antibodies against SARS-CoV-2, the virus that causes COVID-19, 6 months after the second dose of the Pfizer-BioNTech vaccine. Clinical evidence also suggests that the risk [...]
Are the COVID vaccines substantially different from/inferior to other vaccines in terms of their effectiveness? The issue raised, and I'm mostly paraphrasing here, is this: Most vaccines (e.g. measles, smallpox) have efficacy defined such [...]
The EVONANO platform allows scientists to grow virtual tumors and use artificial intelligence to automatically optimize the design of nanoparticles to treat them. The ability to grow and treat virtual tumors is an [...]
Modern Approaches to Augmentation of Brain Function Available from Springer Press This book covers recent advances in neural technology that provide for enhancements for brain function. It addresses a broad range of neural phenomena [...]
Although the currently available COVID-19 vaccines are highly effective, limited manufacturing capacity and the need for cold-chain storage hinder their global distribution. A recent study tested the efficacy of a new adeno-associated virus (AAV) [...]
Fully vaccinated people were 11 times less likely to die of COVID and 10 times less likely to be hospitalized compared to the unvaccinated since highly contagious Delta became the most common variant, US [...]
The highly-infectious Delta coronavirus variant has spread to at least 174 countries worldwide, from the US to Australia, causing a surge in COVID-19 cases. The variant has mutations that help it partially escape the immune response produced by [...]
Fragile mRNA molecules used in COVID-19 vaccines can’t get into cells on their own. They owe their success to lipid nanoparticles that took decades to refine. Messenger RNA (mRNA) is having a moment. This [...]
The COVID-19 pandemic has revealed critical knowledge gaps and assumptions concerning how respiratory viruses spread between hosts. Traditionally thought to be spread mainly through large respiratory droplets produced by the coughs and sneezes of sick individuals, [...]
SARS-CoV-2 is just one of nonillions of viruses on our planet, and scientists are rapidly identifying legions of new species. Mya Breitbart has hunted novel viruses in African termite mounds, Antarctic seals and water [...]
As a team of South African researchers we have identified a new lineage of SARS-CoV-2, the virus causing COVID-19. A lineage represents a genetically distinct virus population with a common ancestor. This virus may be designated as a variant [...]